Landing Your Dream Job In 5 Days
When Eunju Hurh first heard about C4 Therapeutics in February 2021, she fell in love: “I was immediately drawn in by the work C4T was doing to develop small molecule drugs in oncology. It was everything I hoped to get back to in my career.”
However, at the time, Eunju wasn’t actively looking for a new role. She had spent close to a decade in large, global pharmaceutical companies in clinical pharmacokinetics and pharmacology roles developing oncology drugs before leading clinical pharmacology for a small biotech developing and commercializing drugs to treat patients with serious cardiometabolic diseases. After her company was acquired, she knew she wanted to get back to oncology while staying with a small biotech. As fate would have it, C4T had an opening for Vice President, Head of Clinical Pharmacology. Eunju applied through the website one September afternoon.
“C4T moved quickly. The time between my first interview with Talent Acquisition to receiving an offer letter was only five business days,” explained Eunju, now C4T’s Vice President, Head of Clinical Pharmacology. “I was interested in the role immediately, but the interview process solidified that I wanted to join C4T. There was transparency throughout the interview process, and I continue to see that today in C4T leadership and how our teams operate.”
Today, Eunju leads C4T’s clinical pharmacology strategy for our small molecule oncology drugs. As we advance our CFT7455 and CFT8634 programs to Phase 2, Eunju plays an important role in data analyses in close partnership with teams across C4T. She won the annual C4T Excellence Award after being nominated by a colleague who recognized Eunju’s special power: Providing candid and caring feedback that helps individuals and teams leave happy and having learned something.
“I joke that I am impatient, but it’s because I know patients are waiting!” Eunju laughed. “Many of us at C4T proudly wear disease awareness ribbons. I wear these ribbons as a constant reminder of the patients who are waiting for new therapies to treat their diseases. It’s up to all of us to work quickly to bring our medicines to patients who need a new therapeutic option.”
